Join
Live feed
·
PRReleasevia Quantisnow
BioMarin Pharmaceutical Inc. logo
Amicus Therapeutics Inc. logo

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

ByQuantisnow·Wall Street's wire, on your screen.
BMRN· BioMarin Pharmaceutical Inc.FOLD· Amicus Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BMRN (BioMarin Pharmaceutical Inc.), FOLD (Amicus Therapeutics Inc.) and more on Quantisnow.

BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook | Quantisnow